Clinuvel Pharmaceuticals (CUVL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$94.0M

Revenue (quarter)

$94.0M

Revenue growth (year over year)

−1.05%

Gross profit (trailing twelve months)

$78.2M

Gross margin

83.18%

Net income (trailing twelve months)

$33.9M

Net income (quarter)

$33.9M

Net income growth (year over year)

−6.24%

Net margin

36.07%

Return on equity

13.21%

EPS (trailing twelve months)

$0.68

Book value per share

—

P/E (trailing twelve months)

9.07

Price to book

1.13

Debt to assets

7.53%

Payout ratio

—

Dividend yield

—

• Is Clinuvel Pharmaceuticals (CUVL) profitable?

  Yes. Clinuvel Pharmaceuticals earned $33.9M in net income over the trailing twelve months, a net margin of 36.07%.

• How much revenue does Clinuvel Pharmaceuticals (CUVL) make?

  Clinuvel Pharmaceuticals generated $94.0M in revenue over the trailing twelve months, down 1.05% year over year.

• What is CUVL's P/E ratio?

  Clinuvel Pharmaceuticals trades at 9.1 times trailing twelve-month earnings, on an EPS of $0.68.

• How do I buy stock in Clinuvel Pharmaceuticals (CUVL)?

  CUVL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.